Early access
Sign in
Taking people in GermanyPhase 3

Long-term belzutifan treatment for adults with solid tumors or von Hippel-Lindau disease tumors

Continues belzutifan for adults with solid tumors or von Hippel-Lindau-related tumors.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Magdeburg, GermanySee the siteAlso in 9 other countries, 23 sites
Trial code
Registry title
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Status
Recruiting
Phase
Phase 3
People taking part
134 people, planned
Started
12 May 2026
Expected to end
30 Jun 2034
Type of study
Interventional
Record updated
11 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced solid tumors or von Hippel-Lindau-related tumors who are on active treatment in a belzutifan study and want to continue.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced solid tumors or von Hippel-Lindau-related tumors.
Earlier treatment
Must be on active treatment in a belzutifan parent study.

Main reasons for not taking part

  • An ongoing serious adverse event in the parent study, unless no longer hospitalized and clinically stable
  • Currently on a dose interruption because of an adverse event in the parent study

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study

Who cannot take part

  • Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll
  • Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you 18 years old or older?

Where in Germany

Also in 9 other countries, 23 sites

  • Universitaetsklinikum Magdeburg AöRMagdeburg, GermanyTaking people

About the trial

What the trial wants to find out

To assess OS in Cohort A and Cohort B

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Plain-language title
Long-term belzutifan treatment for adults with solid tumors or von Hippel-Lindau disease tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from 2025-524160-38-00, who can take part
Record updated
11 November 2026